NuVasive Inc (NASDAQ: NUVA), a company involved in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced yesterday that it has named Matthew K Harbaugh as its new executive vice president and chief financial officer, effective immediately.
Harbaugh succeeds Rajesh J Asarpota, who will transition from the company.
Harbaugh has more than 25 years of experience in finance, business and strategy, and operations management. Most recently, he served as president of the specialty generics business at Mallinckrodt plc. Prior to that, he was Mallinckrodt's CFO for more than five years. He earlier held various financial management positions at Covidien Pharmaceuticals, which was spun-off from Covidien plc as Mallinckrodt plc in July 2013. He joined Covidien in 2007 and served in several finance and leadership roles, including as CFO and interim president of Covidien Pharmaceuticals. His prior experience includes around 10 years at Monsanto Company, where he held various roles in investor relations and finance and two ex-patriate positions.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer